
    
      Approximately 330 subjects (660 eyes) will be enrolled in this 3 month (12 week) controlled,
      parallel group, masked, randomized study at approximately 15 investigative sites in the
      United States. Subjects will be randomized 2:1 to receive either Asepticys ASP-57
      Multi-Purpose Solution or ReNuÂ® Multiplus Contact Lens Solution (Control) respectively. Both
      Test and Control solution will be used with a rub care regimen.
    
  